

# WHO launches drive to fight bacterial meningitis in Africa

September 8 2022, by FARAI MUTSAKA

---



Dr. Matshidiso Moeti, World Health Organization's regional director for Africa, sits in her office in Brazzaville, Congo, on Feb. 8, 2022. The World Health Organization on Thursday Sept. 8, 2022 said it is launching a \$1.5 billion campaign, hopefully including a new vaccine, to eliminate outbreaks of bacterial meningitis across Africa by 2030. In “a race against time,” WHO regional director for Africa Matshidiso Moeti said that “a next generation” vaccine against meningitis will be rolled out in 26 African countries most affected by the disease. Credit: AP Photo/Moses Sawasawa, File

The World Health Organization on Thursday said it is launching a \$1.5 billion campaign, hopefully including a new vaccine, to eliminate outbreaks of bacterial meningitis across Africa by 2030.

Meningitis vaccinations for more than 50 million children in Africa have been delayed amid the COVID-19 pandemic, prompting fears of a resurgence of the deadly disease.

In "a race against time," WHO regional director for Africa Matshidiso Moeti said that "a [next generation](#)" [vaccine](#) against meningitis will be rolled out in 26 African countries most affected by the disease.

She said WHO hopes to authorize the vaccine by the first quarter of 2023, which would then enable donors to buy it for Africa.

Moeti said the vaccine, "has shown in [clinical trials](#) to be safe and effective against multiple forms of meningitis."

The vaccine could be rolled out next year and administered in widespread drives until 2030, when the WHO hopes to have stopped [bacterial meningitis](#) outbreaks in the continent of 54 countries and 1.3 billion people, she said.

WHO estimated the plan could save more than 140,000 people every year—but that depends on the shot's availability and [health officials](#) being able to administer it.

Although no new cases of meningitis A have been recorded in the past five years on the continent due to a robust vaccination program, the outbreak of the COVID -19 pandemic and attendant restrictions has left "hundreds of millions" of Africans at risk, said Moeti.

Meningitis had "somewhat dropped off the radar" but could now take "an enormous toll on our countries, with COVID-19 threatening some of the extensive gains that had been made in the past," she said during a weekly briefing.

WHO says its reports show that meningitis control activities were reduced by 50% in 2020 compared to 2019 before the COVID-19 outbreak in Africa, although "a slight improvement" was recorded in 2021.

Children are most threatened according to WHO data that shows about half of meningitis cases and deaths occur in children under 5 years of age.

More than 350 million people in 24 high-risk African countries received jabs of the vaccine since 2010, until the [outbreak](#) of the coronavirus pandemic slowed down progress.

Meningitis is a serious infection of the membranes protecting the brain and spinal cord, according to WHO. It is caused by "many different pathogens" that include fungi, viruses and bacteria. Bacterial meningitis is the most deadly, according to the WHO.

Carriers can spread the disease through respiratory or throat fluids via close and prolonged contact like kissing, sneezing or coughing or living close to an infected person.

Meningitis has the potential to cause epidemics and it can lead to death within 24 hours, while one in five patients are left with lifelong disability after infection, according to the WHO.

Symptoms include headache, a stiff neck, sudden onset of fever, nausea or vomiting, feeling drowsy or confused, or developing a sudden dislike

of bright light, according to the WHO.

© 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: WHO launches drive to fight bacterial meningitis in Africa (2022, September 8)  
retrieved 19 November 2023 from

<https://medicalxpress.com/news/2022-09-bacterial-meningitis-africa.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.